Deaths / year
8,000
GBD (indicative unless refreshed)
DALYs / year
400,000
GBD
Pathogen
Virus
Post-infectious
Lasting sequela
Persistent symptoms
n/a
Supplemental viral disease — not on WHO NTD list.
Post-infectious syndrome & persistent symptoms
Whether a post-acute infection syndrome is documented and the literature proportion with persistent symptoms.
Post-acute status
Post-vaccine neurological events (YEL-AND); chronic fatigue in survivors (rare)
Classification
Lasting sequela
Onset
days-to-weeks post-vaccine or post-infection
Persistent-symptom %
not quantified as a single figure (see notes)
Source: WHO yellow fever; Lindsey 2016
Therapeutic agents by stage
Vector control, prevention, acute treatment, and post-infectious care. Only agents with published evidence are shown by default.
Vector & transmission control
| Agent | Type | Status | Mechanism / role | Source |
|---|---|---|---|---|
| Aedes / Haemagogus vector control | Vector control | Approved | Urban & sylvatic transmission reduction | WHO yellow fever |
Prevention
| Agent | Type | Status | Mechanism / role | Source |
|---|---|---|---|---|
| Yellow fever 17D vaccine | Vaccine | Approved | Live attenuated; single dose lifelong immunity in most | WHO EML |
Acute phase
| Agent | Type | Status | Mechanism / role | Source |
|---|---|---|---|---|
| Supportive care (avoid aspirin/NSAIDs) | Supportive | Approved | No specific antiviral; hepatorenal support | WHO EML / standard of care |
| Liver failure & hemorrhage management | Supportive | Approved | Severe viscerotropic disease | WHO EML / standard of care |
| VUNAKIZUMABPipeline | Antibody | Phase 3 | — | Open Targets (clinical pipeline) |
| IVARMACITINIB SULFATEPipeline | Small molecule | Phase 3 | — | Open Targets (clinical pipeline) |
| NAPROXEN ETEMESILPipeline | Small molecule | Phase 3 | — | Open Targets (clinical pipeline) |
| RITUXIMABPipeline | Antibody | Phase 3 | — | Open Targets (clinical pipeline) |
| IVARMACITINIBPipeline | Small molecule | Phase 3 | — | Open Targets (clinical pipeline) |
Post-infectious phase
| Agent | Type | Status | Mechanism / role | Source |
|---|---|---|---|---|
| Post-vaccine adverse event monitoring | Surveillance | Approved | Rare YEL-AND / YEL-AVD after vaccination | WHO |
Associated drug targets (Open Targets): TNF, PTGS2, PTGS1, IL17A, JAK2, NR3C1
Burden: IHME GBD (indicative seed unless refreshed) · Therapeutics: curated WHO EML / SOC + Open Targets pipeline · Post-infectious data: curated peer-reviewed literature · Ontology: MONDO_0005306 · Updated 2026-07-10. Associations, not a diagnostic test.